Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.

"Declarations Ethical approval and consent to participateAll in vivo experiments were approved by the Institutional Animal Care and Use Committee of Shenzhen University (SZU-IACUC-2022–00136) and followed the Guide for the Care and Use of Laboratory Animals. All human breast cancer sample acquisitions were approved by the Committee on Ethics of Shenzhen Second People’s Hospital, Shenzhen University. Written informed consent was obtained from all the participants. Competing interestsThe authors have declared that no competing interest exists. Competing interests The authors have declared that no competing interest exists."

"Funding This project was supported by the National Natural Science Foundation of China, China (No. 82172356, No. 81972003, No.82203559), the Natural Science Foundation of Guangdong, China (No. 2021A1515012144), the Natural Science Foundation of Shenzhen, China (JCYJ20230807115112024), and the Shenzhen High-level Hospital Construction Fund and Medical-Engineering Interdisciplinary Research Foundation of ShenZhen University."